Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Acute hepatitis C frequently transitions to chronic infection, posing a significant public health challenge.
• Early intervention strategies are crucial for preventing long-term sequelae of viral hepatitis.

Purpose of the Study:

• To evaluate the efficacy of short-term interferon (IFN) therapy in preventing chronic hepatitis C when administered during the acute phase.
• To compare the outcomes of early versus delayed IFN intervention in patients with acute hepatitis C.

Main Methods:

• A randomized controlled trial involving 30 patients with acute hepatitis C.
• Two groups: early intervention (IFN-alfa initiated 8 weeks post-onset) and late intervention (IFN-alfa initiated after 1 year).
• Short-term therapy involved 4 weeks of natural IFN-alfa (6 million units daily), with potential follow-up therapy for recrudescence.

Main Results:

• The early-intervention group achieved a sustained virological response (SVR) in 87% of patients after short-term therapy alone, and 100% with follow-up.
• The late-intervention group showed significantly lower SVR rates: 40% after short-term therapy and 53% with follow-up (P = .021 and P = .006, respectively).
• Early initiation of short-term IFN treatment demonstrated superior efficacy in achieving SVR.

Conclusions:

• Short-term (4-week) interferon treatment for acute hepatitis C is effective in preventing chronic infection.
• Initiating IFN therapy during the early acute phase of hepatitis C is critical for optimal treatment outcomes.
• Early IFN intervention offers a promising strategy to improve SVR rates and reduce the burden of chronic hepatitis C.